By Laurent P. Updated on December 7, 2021 at 4:15 pm. Released December 7, 2021 at 4:11 p.m.
Is the treatment against Dosilisumab, Kovit now approved? The European Medicines Agency has confirmed the use of RoActemra (Tocilizumab) for those who have developed a severe form and have already been hospitalized. An anti-inflammatory drug commonly used against arthritis, it has the ability to inhibit the activity of interleukin-6 and prevent cytokine shock and excessive inflammation of the lungs.
A search Processing Against Govt Continuing … TheEuropean Pharmaceuticals Company The application was announced for approval on Monday, December 6th RoActemra (Tocilizumab), An anti-inflammatory drug that helps hospital patients treat and prevent them from developing an acute form of the disease. Also note that this treatment should be used in combination with steroid medication.
An in-depth study of the results and data taken following the marketing demand of Swiss Roche LabsEMA mentioned in a Was contacted Last August 12.
With regard to this treatment, it should be used to treat patients who have already received corticosteroid-based treatment and who have already been admitted to the hospital receiving oxygen. Efficacy already demonstrated in other syndromes. Its action? Avoid chocs cytokinics By blocking the processInterlugin-6, Responsible for excessive inflammation of the lungs: “RoActemra is considered a viable treatment for Govit-19 due to its ability to inhibit the activity of interleukin-6, a substance produced by the body’s immune system in response to inflammation, which plays an important role in Govit-19.“, ExplainsEuropean Pharmaceuticals Company.
Note thatEMA Announced to carry out this treatment, “Accelerated rating“Results of this study were expected.”In mid-October if no additional information is required“The good news is, in any case, the health care arsenal is being treated,” he said. Govt.
“Tv expert. Writer. Extreme gamer. Subtly charming web specialist. Student. Evil coffee buff.”